Phase II Iressa head and neck data

AstraZeneca (AZN; LSE:AZN) reported that in a 52-patient U.S. Phase II study, its Iressa ( ZD1839) EGFR inhibitor gave an overall tumor response rate of 11% in 47 assessed patients with advanced squam...